
Opinion|Videos|August 27, 2026
Adverse Effect Management and Safety Monitoring With Axatilimab
Brooke Adams, PharmD, BCOP, identifies the clinically meaningful adverse effects every pharmacist must monitor—periorbital edema, hepatic enzyme elevations, fatigue—and specifies intervention thresholds (grading, dose modifications, hold criteria) that should trigger escalation conversations with prescribers.
Advertisement
Episodes in this series

Brooke Adams, PharmD, BCOP, identifies the clinically meaningful adverse effects every pharmacist must monitor—periorbital edema, hepatic enzyme elevations, fatigue—and specifies intervention thresholds (grading, dose modifications, hold criteria) that should trigger escalation conversations with prescribers.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
FDA Grants Fast Track Designation to CK0803 for Amyotrophic Lateral Sclerosis
3
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
4
Yeast-Based Universal Flu Vaccine Fully Protects Mice Against 3 Influenza Strains
5































































































